Multifocal Motor Neuropathy
Multifocal Motor Neuropathy (MMN) is a rare neurological disorder characterized by progressive muscle weakness due to damage to the peripheral nerves, often affecting the arms and legs.
Multifocal Motor Neuropathy: DNTH103 Treatment Study
We are testing a new treatment, DNTH103, for adults with multifocal motor neuropathy to see if it improves muscle strength and quality of life. The study will also check its safety compared to a placebo.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 18 and 75 years old?
- Do you have a confirmed diagnosis of MMN (multifocal motor neuropathy)?
- Are you currently pregnant or breastfeeding?
- Are you taking any medications like rituximab, cyclophosphamide, or mycophenolate mofetil?
- Have you had any major surgery or significant medical condition in the last year?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Dnth103
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Aarhus Universitetshospital
Neuromuscular Clinic
Århus, Denmark
Rigshospitalet
Neuromuscular Clinic and Research Unit
Copenhagen, Denmark
Centre Hospitalier Henri Mondor
Neurology
Aurillac, France
Sponsor: Dianthus Therapeutics Inc.
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.